DUBLIN–(BUSINESS WIRE)–The “Devic’s Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering.
Devic’s syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 217.7 Mn in 2021 and projected to grow at a CAGR of 12.0% during the forecast period from 2022 to 2030.
Soliris (Eculizumab) will aid the significant growth of Devic’s Syndrome treatment market throughout the forecast period
Soliris (Eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic s syndrome. Patients suffering with Devic’s syndrome possess AQP4 antibody-positive, the body s immune system can turn against itself to produce autoantibodies against AQP4.
Activation of anti-AQP4 autoantibodies leads to damage of vital cells in the CNS assisting further demyelination and death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in Devic s syndrome treatment pipeline such as Satralizumab – Phase 3 (Hoffmann-La Roche/ Chugai Pharmaceutical), MEDI-551- Phase 2/3 (MedImmune LLC), and RC18 – Phase 3 (RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on 15 October 2020; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
North America dominated the overall global market specifically due to recent drug approval, promising drugs in pipeline, and developed diagnostic landscape
In 2021, North America dominated the market and anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirement for target-specific molecules to treat Devic s Syndrome, and easy adaptability & accessibility for newly launched drug. According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic’s syndrome in the United States with majority of women population. Asia Pacific will grow during the forecast period from 2022 to 2030, due to increasing awareness related to Devic s Syndrome assisting the rise in diagnosis & treatment rate in patients suffering with rare diseases.
Market Segmentation
Drugs
- Eculizumab
- Methylprednisolone
- Azathioprine
- Mycophenolate Mofetil
- Rituximab
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Devic’s Syndrome Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Devic’s Syndrome Treatment market?
- Which is the largest regional market for Devic’s Syndrome Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Devic’s Syndrome Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Devic’s Syndrome Treatment market worldwide?
Key Topics Covered:
1. Preface
2. Executive Summary
3. Devic’s Syndrome Treatment Market: Competitive Analysis
4. Devic’s Syndrome Treatment Market: Macro Analysis & Market Dynamics
5. Devic’s Syndrome Treatment Market: By Drugs, 2020-2030, USD (Million)
6. North America Devic’s Syndrome Treatment Market, 2020-2030, USD (Million)
7. UK and European Union Devic’s Syndrome Treatment Market, 2020-2030, USD (Million)
8. Asia Pacific Devic’s Syndrome Treatment Market, 2020-2030, USD (Million)
9. Latin America Devic’s Syndrome Treatment Market, 2020-2030, USD (Million)
10. Middle East and Africa Devic’s Syndrome Treatment Market, 2020-2030, USD (Million)
11. Company Profile
Companies Mentioned
- Alexion Pharmaceuticals Inc.
- Teva Pharmaceuticals
- Fresenius Kabi AG
- Pharmacia & Upjohn (a subsidary of Pfizer)
- Mylan Pharmaceuticals Inc.
- Chugai Pharmaceutical
- MedImmune LLC
- and RemeGen Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/rj559e
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900